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Abstract 
 
Epigenetic patterns on the level of DNA methylation have already shown to separate clinically relevant 
subgroups of meningiomas. We here set out to identify potential prognostic implications of epigenetic 
modification on the level of histones with focus on H3K27 trimethylation (H3K27me3). H3K27me3 was 
assessed by immunohistochemistry on 232 meningiomas from 232 patients. In 194 cases, trimethylation 
was detected in tumor cells. In 25 cases, staining was limited to vessels while all tumor cells were 
negative. Finally, 13 cases yielded equivocal staining patterns. Reduced abundance of H3K27me3 in 
cases with staining limited to vessels was confirmed by mass spectrometry on a subset of cases. Lack of 
staining for H3K27me3 in all tumor cells was significantly associated with more rapid progression 
(p=0.009). In line, H3K27me3 negative cases were associated with a DNA methylation pattern of the 
more aggressive types among the recently introduced DNA methylation groups. Also, NF2 and SUFU 
mutations were enriched among cases with complete lack of H3K27me3 staining in tumor cells 
(p<0.0001 and p=0.029, respectively). H3K27me3 staining pattern added significant prognostic insight in 
WHO grade II cases and in the compound subset of WHO grade I and II cases (p=0.04 and p=0.007, 
respectively). However, it did not further stratify within WHO grade III cases. Collectively, this data 
indicate that epigenetic modifications beyond DNA methylation are involved in the aggressiveness of 
meningioma. It also suggests that H3K27me3 immunohistochemistry might be a useful adjunct in 
meningioma diagnostics, particularly for cases with WHO grade II histology or at the borderline between 
WHO grade I and II. 
 
 
  
Introduction 
 
Meningiomas are the most frequent primary intracranial and spinal tumors. They are classified into WHO 
grades I to III. Grading is based on histological features [18]. This histological system, as per se all 
classificatory approaches, is imperfect; particularly, WHO grade I meningiomas can recur and infiltrate 
locally and, conversely, higher grade meningiomas can have an indolent clinical course [10]. 
 
Despite its limitations, the WHO grading system is the best currently available algorithm for risk 
stratification of meningiomas. Thus, it defines clinical management, with clear guidelines for grades I and 
III, recommending observation and adjuvant radiation, respectively. Grade II meningiomas, however, 
comprise a histologically heterogeneous group of tumors with behavior that is more challenging to 
predict, leaving treatment decisions to be determined by institutional multidisciplinary consensus rather 
than formalized guidelines [10]. Treatment determination hinges on an imprecise balance between 
likelihood of recurrence and potentially latent treatment-induced morbidity. Thus, further improvement of 
the classification is needed, potentially employing novel, more reliable biomarkers.  
 
Besides the previously known mutations in NF2, genome wide and subsequent targeted sequencing 
studies of meningiomas have identified recurrent mutations in AKT1/TRAF7, KLF4/TRAF7, SMO, and 
PIK3CA which are strongly associated with histological features and location 
[2,3,5,26,33,38].  Additionally, mutations in the TERT promoter are associated with higher risk of 
recurrence and shorter progression free survival [11,23,29].  
 
Epigenetic modifications may also indicate the risk of recurrence in meningiomas [5,7,8,12,16,35]. 
Consequently, recent reports propose risk stratification schemes based on DNA methylation subgroups 
[21,30]. 
 
Besides DNA methylation, a major epigenetic determinant of gene expression and cellular differentiation 
is the modification of histones, primarily by methylation and acetylation. Particularly modifications of 
lysine 27 (K27) of histone H3 play a crucial role in tumorigenesis [37]. Methylation of H3K27 is 
regulated by the EZH2 subunit of the PRC2 complex [4,20,36] and trimethylated H3K27 (H3K27me3) is 
associated with silencing of genes in the accompanying region [17].  Dysregulation of H3K27 
methylation has been identified in several different cancers, including breast, prostate, colon, ovarian 
cancers, and malignant peripheral nerve sheath tumors [6,15,24,31,37,39,40]. As a result, assessment of 
H3K27 methylation status, particularly trimethylation (H3K27me3) has entered diagnostic practice as an 
immunohistochemical tool for several entities [1,22].  
 
We here tested for H3K27me3 staining patterns in meningioma in order to detect potentially clinically 
relevant subgroups identified by this marker. 
  
Materials and Methods 
 
Case cohort 
We assessed formalin-fixed paraffin embedded tissue of 232 meningiomas of 232 patients. Since 
meningiomas at the interface of the common grade I and the less frequent grade II are most challenging to 
predict in terms of clinical course, the study was intentionally enriched for WHO grade II cases compared 
to epidemiological distribution (Table 1). Of note, all but two cases of WHO grade II were diagnosed 
based on mitotic count, the other two based on brain invasion. Of cases with recurrences, only material 
from the primary lesion was assessed. Based on information from available clinical records, no patient 
had prior radiotherapy or known neurofibromatosis type 2. Tumor size was estimated by measuring the 
largest diameter of contrast-enhancing tumor lesions in one plain on available imaging scans (CT or 
MRI). The cases and clinical data were provided by the Dept. of Neurology Zurich (Switzerland), the 
Dept. of Neuropathology Frankfurt (Germany), the Dept. of Pathology at the NYU Langone Medical 
Center (USA), and the Depts. of Neurosurgery, Neurology and Neuropathology Heidelberg (Germany). 
The tissues from Frankfurt were assessed on tissue micro arrays with two cores of each 2 mm diameter 
from each case. All other cases were analyzed as whole sections. Research use of tissue and clinical data 
was in accordance with local ethical regulations. Diagnoses were based on the WHO classification of 
brain tumors 2016. Cases initially diagnosed based on previous versions of the classification were 
reviewed (Zurich and Heidelberg samples in Heidelberg, other cases at the respective local institutions).  
 
Immunohistochemistry and molecular analysis 
Immunohistochemistry was performed on 4 µm-thick formalin-fixed, paraffin-embedded (FFPE) tissue 
sections. Tissues were pre-treated for 10 min at 121°C in an autoclave at 210 kPA, subsequently further 
incubated with Ventana Cell Conditioner 1 immunostainer (Ventana Medical Systems, Tucson, AZ, 
USA) for 1 h.   This pre-treatment was followed by incubation with rabbit monoclonal H3K27me3 
antibody C36B11 (1:100, Cell Signaling, Danvers, MA, USA) on a Ventana BenchMark Ultra automated 
stainer for 2 h. Standard Ventana signal amplification was used including OptiView Amplifier Multimer 
and incubation with hematoxylin and Blueing reagent for 4 min each. Intratumoral vessels served as 
positive controls. DNA methylation and panel sequencing data were obtained from previous analyses 
[30]. 
 
Statistics 
Fisher's exact test was used to compare categorical factors between H3K27 groups. Mann-Whitney test 
was used to compare quantitative parameters between H3K27 groups. Time to progression (TTP) was 
defined as time from initial surgery to 1st recurrence as determined by imaging. Patients without 
recurrence during follow-up were censored at last follow-up. Kaplan-Meier estimates and log-rank test 
were used to estimate and compare distribution of TTP between groups. Cox regression was used to 
assess the impact of factors on TTP. Interaction between WHO grade and H3K27 was tested in Cox 
regression in order to identify subgroup effects. Cox Regression with Firth correction [13] was used in 
case of complete separation. For multivariable Cox regression model, multiple imputations of missing 
values with 100 imputations were performed using the chained equations (mice) algorithm [34]. 
Associations of staining patterns with mutations were analyzed with Fisher’s exact test. P-values below 
0.05 were considered statistically significant. Analysis was performed with statistical software R 3.4 
(https://www.R-project.org/).  
 
Mass spectrometry for histone modification 
Nine frozen meningioma samples (from Zurich and Heidelberg) were available for mass spectrometry 
analysis. Histones were acid extracted, derivatized via propionylation, digested with trypsin, newly 
formed N-termini were propionylated as previously described [9] at ActiveMotif (Carlsbad, CA, USA), 
and then measured 3 separate times using the Thermo Scientific TSQ Quantum Ultra mass spectrometer 
coupled with an UltiMate 3000 Dionex nano-liquid chromatography system. The data was quantified 
using Skyline [19]. 
  
Results 
 
 
Of 232 assessed cases, 194 showed positive staining for H3K27me3 in vessels and tumor cells, indicating 
trimethylation at H3K27 in the majority of meningiomas (Table 1). In 25 cases, however, H3K27me3 
staining was limited to vessels while tumor cells were negative for this marker, pointing towards a loss of 
trimethylation (Fig. 1a, b). Cases with positive staining for H3K27me3 were subsequently tagged 
“retained” while cases without H3K27me3 in tumor cells were designated as “loss”. Of note, 13 cases had 
retained trimethylation with intermingled areas of negative staining. In these cases with ambiguous 
staining pattern, the vessels were also faintly stained or negative for H3K27me3 in the areas with negative 
tumor cells (Fig 1c, d). Thus, this pattern of partial loss is more likely an artifact than due to a sub-clonal 
event. Consequently, these cases were grouped with the "retained” cases. 
 
Cases with complete loss of trimethylation showed significantly less favorable outcome and more rapid 
progression (p=0.009, Fig. 2a). This also held true when limiting the analysis to cases with clearly 
positive or negative H3K27me3 staining in tumor cells, excluding the cases with ambiguous pattern 
(Suppl. Fig. 1, p=0.01). While this survival analysis was applied to the entire un-stratified cohort, for 
potential application in diagnostic routine, however, the added value on top of the current grading is more 
relevant. Interestingly, when further dissecting this overall discriminatory effect by the WHO grades, it 
was actually limited to WHO grade I and II (Fig 2b, c). All WHO grade II cases with complete loss were 
diagnosed as atypical based on mitotic count. In contrast, histologically clearly anaplastic cases could not 
be further sub-divided for prognostic sub-groups by H3K27me3 staining pattern (Suppl. Fig. 2) and 
showed in fact a significantly different prognostic impact of H3K27me3 than WHO I/II cases (interaction 
test p=0.02). 
H3K27me3 staining, WHO grade, extent of resection (STR vs. GTR and Simpson grade) were all 
significantly associated with outcome in a univariable analysis of WHO grade I and II cases (Table 2). 
H3K27me3 staining pattern remained prognostically relevant when adjusting this subset for WHO grade 
and extent of resection in a multivariable analysis (Table 3).  
 
Mutational status and DNA methylation subgroups 
Mutational data was available for 98 cases. Among the most frequently mutated genes in meningioma, 
encompassing AKT1, KLF4/TRAF7, NF2, PIK3CA, SMO, SUFU and the TERT promoter, only mutations 
of NF2 and SUFU were significantly more frequent in cases without H3K27 trimethylation (p<0.001 and 
p=0.029, respectively, Suppl. Table 1). Other recurrent mutations, including aberrations of genes coding 
for histones that can also be associated with loss of trimethylation, were not detected. 
Also, the DNA methylation status of 87 samples was analyzed in context of the H3K27me3 staining 
pattern. Case numbers with complete loss of trimethylation were too small to assess association with the 
previously introduced six individual DNA methylation subgroups [30]. Thus, an analysis for association 
with the two overarching DNA methylation groups “A” (comprising the three benign subgroups and 
subgroup intermediate-A) and “B” (comprising subgroups intermediate-B and malignant) was performed. 
Therein, complete loss of trimethylation was significantly associated with a DNA methylation pattern of 
the “group B”, comprising the subgroups “MC malignant” and “MC intermediate B” (p=0.0046, Fisher’s 
exact test, Suppl. Table 2, Suppl. Fig.3).  
 
Mass spectrometry screen for histone modification 
In order to assess the broader landscape of epigenetic regulation by histone modification, we performed a 
mass spectrometry-based screen for >80 histone modifications. Availability of sufficient frozen tissue and 
cost per analysis restricted the case selection and sample size. The analysis included two samples with 
complete loss of H3K27me3, assigned to group B by DNA methylation analysis (subgroups MC 
malignant and MC intermediate-B) and seven cases with retained trimethylation from group A (each three 
from MC benign-2 and benign-1 and one from MC intermediate A). Unsupervized clustering of these data 
yielded a pattern that exactly recapitulated the groups assigned by DNA methylation analysis (Fig. 3). 
Trimethylation of H3K27me (H3.1 and H3.3) was significantly lower in group B cases (p=0.003 and 
p=0.04, respectively).  
 
 
 
  
Discussion 
 
Associations between epigenetic modification and aggressiveness in meningioma have so far mostly been 
assessed on the level of DNA methylation. Thereby, DNA methylation analysis has evolved as promising 
candidate to add a molecular layer to upcoming WHO classifications, along with risk-related genetic 
aberrations like TERT promoter or BAP1 mutations [11,14,23,29,32].  
 
However, the major alternative epigenetic modifier, histone methylation and acetylation, has not been 
further evaluated for prognostic potential. Yet, associations of H3K27-related regulation of expression 
and molecular subgroups of meningioma have already been reported. On the basis of chromatin 
immunoprecipitation sequencing (ChIP Seq) for the regulatory mark H3K27Ac, the chief competing 
modification to trimethylation, differences between meningioma with AKT1 vs. NF2 mutations have been 
reported [5]. 
 
In contrast to ChIP-Seq and DNA methylation analysis, H3K27me3 immunohistochemistry is already 
implemented in many laboratories and can be readily applied. Its diagnostic potential has already been 
demonstrated for malignant peripheral nerve sheath tumors (MPNST) and ependymomas [22,27]. In both 
entities, MPNST and posterior fossa ependymoma, the H3K27me3 staining pattern parallels a distinct 
DNA methylation. Also in our cohort, the H3K27me3 staining was associated with the previously 
introduced DNA methylation subgroups. In MPNST, the loss of trimethylation is mechanistically 
attributable to the perturbed PRC2 complex as result of the EED/SUZ12 alterations [25]. For 
ependymomas and meningiomas, the functional background is not yet fully deciphered.  
 
Although a merely descriptive finding, our data show that immunohistochemistry for H3K27me3 on 
meningioma samples can provide a useful tool in neuropathology practice. Complete loss of H3K27me3 
staining predicts increased risk of recurrence in meningiomas, for the group of WHO grade I/II cases even 
independent of histological grade or extent of resection. While complete loss of trimethylation also 
occurred in WHO grade III cases, the staining pattern did not further stratify for risk-related subgroups 
among them. This might be due to other factors driving malignancy irrespective of H3K27 status. Also, 
an effect might be obscured by the study design that did not stratify for treatment. The majority of the 
high-grade cases might have received adjuvant therapy. However, only limited information on this was 
available for the present study which prevents definitive assessment of H3K27 trimethylation as a 
biomarker in WHO grade III meningiomas. Further, the fact that complete loss of trimethylation is 
associated with worse outcome within the entire cohort but not an obligatory prerequisite for high-grade 
meningiomas may also explain why a previous study could detect higher H3K27 trimethylation in a 
subset of WHO grade II cases compared to low grade meningioma [12].  
 
Of note, a challenge in application of H3K27me3 staining remains that different specificities have been 
reported for the various available antibodies [28]. More advanced proteomic methods including mass 
spectrometry will potentially elucidate which specific methylation status is detected at which specific 
sites and by which clones. Importantly, these studies may identify whether there is actually a functional 
background and relevance of these discrepant antibody specificities. By now, incorporation of this 
immunohistochemical biomarker as outlined here has the potential to predict which meningiomas are 
more likely to recur, helping to identify those patients that may benefit from adjuvant radiation or a more 
stringent clinical and radiological follow-up. Future larger and prospective studies stratifying patients 
based on H3K27me3 status are warranted to further validate its use in diagnostic routine and its 
correlation with mutations and DNA methylation. 
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Figure legends 
 
Figure 1: Examples of meningiomas positive (a) and negative (b) for H3K27me3 staining, and examples 
with indeterminate staining pattern (c, d). Scale bar: 50 µm 
 
Figure 2: Kaplan-Meier curves showing time-to-recurrence for all analyzed meningiomas (a) and 
restricted to cases of WHO grade I/II (b), stratified for H3K27me3 staining, with number of 
patients/events given in parenthesis. Hazard ratio for H3K27me (c): The first five lines (I, II, I/II, III, all) 
are based on univariable Cox regression models for H3K27me in the respective WHO grade subgroup. 
Line 6 (I/II adjusted) is based on the multivariable Cox regression model in the subgroup of WHO grade 
I/II patients (table 3). Wald test p-values are given. 
 
Figure 3: Unsupervised clustering of mass spectrometry for histone modifications. Two samples are 
derived from meningioma methylation Group (MG) B, seven from meningioma methylation Group A. 
Highlighted are H3.1K27me3 and H3.3K27me3.  
Table 1 Characteristics of the Cohort 
 
Parameter  Subcategory retained  loss  p  
n / [%]   207 89% 25 11%   
WHO Grade I 48 23% 1 4% 
0.02   II 137 66% 18 72% 
  III 22 11% 6 24% 
Sex F 123 59% 14 56% 
0.67 
  M 80 39% 11 44% 
Simpson Grade 1 61 29% 10 40% 
0.24 
  2 63 30% 6 24% 
  3 13 6% 5 20% 
  4 33 16% 3 12% 
  5 2 1% 0 0% 
EOR GTR 155 78% 22 88% 
0.31 
  STR 43 22% 3 12% 
Subtype Secretory 8 4% 0 0% 
0.86 
  Meningiothelial 7 3% 0 0% 
  Transitional 8 4% 1 4% 
  Fibrous 8 4% 0 0% 
  Psammomatous 5 2% 0 0% 
  Angiomatous 5 2% 0 0% 
  Microcystic 5 2% 0 0% 
  Metaplastic 1 0% 0 0% 
  Lymphoplasmacyte-rich 1 0% 0 0% 
  Atypical 126 61% 17 68% 
  Chordoid 10 5% 1 4% 
  Clear cell 1 0% 0 0% 
  Anaplastic 20 10% 6 24% 
  Papillary 1 0% 0 0% 
  Rhabdoid 1 0% 0 0% 
              
Age (median [IQR])   56.00  
[46.00, 
66.00] 
56.00  
[47.00, 
70.00] 
0.75 
Diameter (median 
[IQR]) 
  42.00  [34.00, 
50.00] 
47.00  [45.00, 
66.00] 
0.19 
 
  
Legend to Table 1:  
Characteristics of the case cohort in absolute numbers and percentages. f – female, m – male, retained – 
tumor cells were positive for H3K27me3 staining, loss – complete loss of H3K27me3 staining in tumor 
cells. Extent of resection (EOR) was available for 198 cases in the categories “gross total resection” 
(GTR) and “subtotal resection” (STR) and for 172 cases additionally as Simpson grade. Age and diameter 
in millimeters are given in median values with inter-quartile ranges (IQR). p – p-values. For categorical 
parameters, p-value of Fisher’s exact test is given. For continuous parameters, p-value of Mann-Whitney 
test is given. 
 
 
  
Table 2 Univariable Cox regression models on WHO grade I/II cases 
Parameter 
 
N Events HR 95%-CI p-value 
H3K27me3 loss vs. retained 204 61 2.64 1.28-5.46 0.0088 
WHO grade II vs. I 204 61 2.91 1.55-5.47 0.0009 
Extent of resection STR vs. GTR 195 54 2.03 1.10-3.73 0.02 
Simpson grade per degree increase 171 47 1.34 1.04-1.72 0.02 
Age per 10 year increase 204 61 0.92 0.75-1.13 0.43 
Sex male vs. female 200 59 1.25 0.74-2.10 0.41 
Diameter per 10 mm increase 60 20 1.04 0.80-1.34 0.77 
  
Legend to Table 2: 
N – number of cases included in analysis, HR – hazard ratio, CI – confidence interval, GTR – gross total 
resection, STR – subtotal resection, mm – millimeter.   
 
 
  
Table 3 Multivariable Cox regression model on WHO grade I/II cases 
Parameter 
  
 HR  95%-CI p-value 
H3K27me3 loss vs. retained 
 
 
2.30 1.09-4.81 0.028 
WHO grade II vs. I 
 
2.71 1.40-5.24 0.003 
Extent of resection STR vs. GTR 
 
1.59 0.86-2.96 0.14 
Age per 10 year increase 
 
0.90 0.74-1.09 0.26 
Sex male vs. female 
 
0.99 0.57-1.71 0.96 
      
  
Legend to Table 3: 
Multivariable Cox regression model with missing value imputation on 204 cases with 61 events. HR – 
hazard ratio, CI – confidence interval, GTR – gross total resection, STR – subtotal resection. Since extent 
of resection  in the categories STR vs. GTR was known for more samples than exact Simpson grade and 
both parameters are closely related, only STR vs. GTR was included in the analysis. The number of cases 
with information on tumor diameter was too low to be included in multivariable analysis.    
 



